Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab and Durvalumab with Ablation in HCC and BTC
NCT02821754Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2016
- Primary completion
- Feb 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tremelimumab, durvalumab in hepatocellular carcinoma (HCC), biliary tract carcinoma (BTC), sponsored by National Cancer Institute. Started Jul 2016; status: completed.
02
Drugs
tremelimumabdurvalumab
03
Conditions
hepatocellular carcinoma (HCC)biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT02821754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02821754.